Immunic Inc (IMUX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $102.61M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immunic Inc (IMUX) Earnings: Report Dates and Results
Immunic (IMUX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Immunic reported EPS of -$0.99, below the -$0.82 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IMUX has an expected report date of Feb 24, 2027.
IMUX Earnings Call
The latest IMUX earnings call transcript on file is labeled 2024Q3.
Read the 2024Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, IMUX beat 15, missed 21 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2019, when EPS landed 123.53% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.99 | -$0.82 | -$2.58 - -$0.67 | -20.73% | Miss | N/A | 12 | 7 up, 3 down | Nov 13, 2026 |
| Jun 30, 2026 | -$0.80 | -$1.24 | -$2.41 - -$0.63 | +35.48% | Beat | N/A | 10 | 2 up, 4 down | Aug 11, 2026 |
| Mar 31, 2026 | -$1.08 | -$0.96 | -$2.00 - -$0.50 | -12.50% | Miss | N/A | 7 | 2 up, 2 down | May 13, 2026 |
| Dec 31, 2025 | -$0.12 | -$0.10 | -$0.26 - -$0.07 | -20.00% | Miss | N/A | 9 | 0 up, 1 down | Feb 26, 2026 |
| Sep 30, 2025 | -$1.30 | -$1.77 | -$2.70 - -$1.10 | +26.55% | Beat | N/A | 9 | 2 up, 3 down | Nov 13, 2025 |
| Jun 30, 2025 | -$0.20 | -$0.18 | -$0.26 - -$0.05 | -11.11% | Miss | N/A | 6 | 4 up, 1 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.25 | -$0.25 | -$0.26 - -$0.16 | 0.00% | In line | N/A | 7 | 1 up, 1 down | May 15, 2025 |
| Dec 31, 2024 | -$2.50 | -$2.38 | -$2.60 - -$2.20 | -5.04% | Miss | N/A | 6 | 0 up, 6 down | Mar 31, 2025 |
| Sep 30, 2024 | -$2.40 | -$2.18 | -$2.30 - -$1.90 | -10.09% | Miss | N/A | 5 | 0 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$2.10 | -$2.33 | -$2.40 - -$2.20 | +9.87% | Beat | N/A | 3 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$3.00 | -$2.65 | -$3.20 - -$2.30 | -13.21% | Miss | N/A | 5 | 0 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$0.48 | -$0.51 | -$0.56 - -$0.43 | +5.88% | Beat | N/A | 4 | 0 up, 0 down | Feb 22, 2024 |
| Sep 30, 2023 | -$5.10 | -$5.07 | N/A | -0.59% | Miss | N/A | 4 | 0 up, 0 down | Nov 14, 2023 |
| Jun 30, 2023 | -$5.40 | -$5.12 | -$5.80 - -$4.50 | -5.47% | Miss | N/A | 4 | 0 up, 0 down | Aug 3, 2023 |
| Mar 31, 2023 | -$5.80 | -$4.80 | -$6.00 - -$4.50 | -20.83% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$5.88 | -$7.42 | -$13.90 - -$3.90 | +20.75% | Beat | N/A | 4 | 1 up, 1 down | Feb 23, 2023 |
| Sep 30, 2022 | -$6.90 | -$6.95 | -$7.00 - -$5.60 | +0.72% | Beat | N/A | 6 | 0 up, 0 down | Nov 3, 2022 |
| Jun 30, 2022 | -$7.20 | -$7.30 | -$8.40 - -$6.40 | +1.37% | Beat | N/A | 5 | 0 up, 0 down | Aug 4, 2022 |
| Mar 31, 2022 | -$7.40 | -$7.57 | -$9.00 - -$7.00 | +2.25% | Beat | N/A | 7 | 0 up, 0 down | May 10, 2022 |
| Dec 31, 2021 | -$0.72 | -$0.76 | -$0.99 - -$0.66 | +5.26% | Beat | N/A | 8 | 0 up, 0 down | Feb 24, 2022 |
| Sep 30, 2021 | -$7.60 | -$7.52 | -$9.40 - -$5.90 | -1.06% | Miss | N/A | 8 | 0 up, 1 down | Nov 4, 2021 |
| Jun 30, 2021 | -$8.20 | -$6.67 | -$7.80 - -$3.70 | -22.94% | Miss | N/A | 8 | N/A | Aug 6, 2021 |
| Mar 31, 2021 | -$8.14 | -$6.85 | -$7.40 - -$6.00 | -18.83% | Miss | N/A | 7 | N/A | May 6, 2021 |
| Dec 31, 2020 | -$0.46 | -$0.60 | -$0.75 - -$0.28 | +23.33% | Beat | N/A | 6 | N/A | Feb 26, 2021 |
| Sep 30, 2020 | -$7.00 | -$6.47 | -$7.70 - -$5.50 | -8.19% | Miss | N/A | 7 | N/A | Nov 5, 2020 |
| Jun 30, 2020 | -$9.00 | -$7.27 | -$8.00 - -$5.70 | -23.80% | Miss | N/A | 4 | N/A | Aug 2, 2020 |
| Mar 31, 2020 | -$0.79 | -$0.95 | -$0.96 - -$0.95 | +16.84% | Beat | N/A | 2 | N/A | May 8, 2020 |
| Dec 31, 2019 | -$7.50 | -$7.60 | -$7.60 - -$7.60 | +1.32% | Beat | N/A | 1 | N/A | Mar 16, 2020 |
| Sep 30, 2019 | -$8.20 | -$6.50 | -$6.90 - -$6.50 | -26.15% | Miss | N/A | 2 | N/A | Nov 7, 2019 |
| Jun 30, 2019 | -$15.20 | -$6.80 | N/A | -123.53% | Miss | N/A | N/A | N/A | Aug 8, 2019 |
| Mar 31, 2019 | -$0.91 | -$0.59 | -$0.59 - -$0.59 | -53.39% | Miss | N/A | 1 | N/A | Apr 10, 2019 |
| Dec 31, 2018 | -$2.40 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 4, 2019 |
| Sep 30, 2018 | -$11.20 | -$11.20 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2018 |
| Jun 30, 2018 | -$12.00 | -$13.20 | N/A | +9.09% | Beat | N/A | N/A | N/A | Aug 7, 2018 |
| Mar 31, 2018 | -$13.60 | -$13.60 | N/A | 0.00% | In line | N/A | N/A | N/A | May 8, 2018 |
| Dec 31, 2017 | -$14.00 | -$12.40 | N/A | -12.90% | Miss | N/A | N/A | N/A | Mar 13, 2018 |
| Sep 30, 2017 | -$12.00 | -$12.80 | N/A | +6.25% | Beat | N/A | N/A | N/A | Oct 25, 2017 |
| Jun 30, 2017 | -$11.60 | -$14.13 | N/A | +17.91% | Beat | N/A | N/A | N/A | Aug 3, 2017 |
| Mar 31, 2017 | -$15.60 | -$14.60 | N/A | -6.85% | Miss | N/A | N/A | N/A | May 9, 2017 |
| Dec 31, 2016 | -$14.80 | -$14.20 | N/A | -4.23% | Miss | N/A | N/A | N/A | Mar 7, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.87, after -$10.00 the year before. It was -$52.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.87 | N/A |
| Dec 31, 2024 | -$10.00 | N/A |
| Dec 31, 2023 | -$16.78 | N/A |
| Dec 31, 2022 | -$27.38 | N/A |
| Dec 31, 2021 | -$24.66 | N/A |
| Dec 31, 2020 | -$17.25 | N/A |
| Dec 31, 2019 | -$31.81 | N/A |
| Dec 31, 2018 | -$39.20 | N/A |
| Dec 31, 2017 | -$53.20 | N/A |
| Dec 31, 2016 | -$52.00 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q3 for the period ended Sep 30, 2024, runs about 6,000 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q3 | Sep 30, 2024 | 5,979 | 8 |
2024Q3 Earnings Call
Opening remarks
Jessica Breu Vice President, Investor Relations and Communications Good morning, and welcome to Immunic’s Third Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer, Glenn Whaley, our Chief Financial Officer; as well as Jason Tardio, our President and Chief Operating Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today’s presentation, there will be an opportunity to ask questions. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning. And, such statements involve a number of risks and uncertainties that could cause Immunic’s actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic’s opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic’s SEC filings for a more detailed description of the risk factors that may affect Immunic’s results and these forward-looking statements. I would now like to turn the call over to our CEO, Dr. Daniel Vitt, to begin the presentation. Daniel?
Daniel Vitt CEO Thank you, Jessica. I would also like to welcome everybody to today’s Q3 2024 earnings call. Earlier this morning, we announced our financial results for the third quarter and nine months ended September 30, 2024. During the call today, we will walk through our third quarter 2024 achievements and subsequent highlights, financial and operating results as well as our clinical development programs, including anticipated upcoming milestones. As Jessica noted, after the presentation, you will have the opportunity to ask questions. Let’s start with the review of our third quarter 2024 and subsequent highlights. In July, our management team was strengthened with the addition of Jason Tardio, as President and Chief Operating Officer, bringing with him a wealth of experience launching and commercializing multiple sclerosis drugs for major biotechnology and pharmaceutical companies. Jason has already proven to be invaluable, leading internal efforts to prepare for the potential commercialization of vidofludimus calcium. Jason also has been collaborating closely with Patrick Walsh, our Chief Business Officer, to prepare the company for a range of potential partnership outcomes for vidofludimus calcium as well as our other drug candidates, where we are leveraging his extensive partnering experience. Additionally, Werner Gladdines was promoted to Chief Development Officer.
Frequently Asked Questions About IMUX
When is Immunic's next earnings date?
Immunic's next earnings report is expected for Feb 24, 2027.
Did IMUX beat earnings estimates last quarter?
No. Immunic reported EPS of -$0.99 for the quarter ended Sep 30, 2026, below the -$0.82 estimate by 20.73%.
What EPS do analysts expect from IMUX next quarter?
The consensus EPS estimate for Immunic for the quarter ending Dec 31, 2026 is -$0.82 from 13 analysts, with estimates from -$1.23 to -$0.60.
How often does IMUX beat earnings estimates?
Immunic beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -0.92%.
IMUX pages: Overview, Earnings, Forecast, Financials, Competitors